PHAR, EGS38081C013

EIPICO stock: Holding-company profit falls 30%

Published on 11/19/2026 at 01:19 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
EIPICO stock faces a mixed nine-month report, with revenue growth offset by lower consolidated profit. An auditor reservation adds a fresh reporting issue for investors.

Earnings and reporting update

  • Consolidated net revenue increased to EGP 7.389 billion in the first nine months of 2026.
  • EIPICO attributed the auditor's reservation to missing financial statements from Medical Professions for Pharmaceuticals.
  • The company expects to recognize its share of the affiliate's results when the required information becomes available.
PHAR, EGS38081C013, Illustration mit AI erstellt.

Egyptian International Pharmaceutical Industries Company, known as EIPICO, reported a sharp decline in earnings for the first nine months of 2026 on November 15. Consolidated net profit attributable to the holding company fell 30.14 percent year on year to EGP 792.973 million, from EGP 1.135 billion, according to Zawya.

Revenue growth meets earnings pressure

Consolidated net revenue rose 3.22 percent to EGP 7.389 billion in the January-to-September period, compared with EGP 7.158 billion a year earlier. The figures show that higher sales did not translate into stronger attributable earnings during the period.

Standalone net profit after tax declined 39.33 percent to EGP 535.659 million from EGP 882.850 million in the corresponding period of 2025. Investors will therefore focus on cost trends, financing expenses and the contribution from EIPICO's associated companies as the company moves toward its full-year accounts.

Auditor reservation explained

On November 17, EIPICO explained that the reservation in the review report on its consolidated interim statements arose because financial statements from Medical Professions for Pharmaceuticals were unavailable. The affiliate is accounted for under the equity method, and EIPICO said the missing information prevented it from recording its share of the affiliate's results and changes in net assets, as reported by Youm7.

The book value of the investment was about EGP 374.9 million, equal to approximately 1.95 percent of consolidated assets. EIPICO said it is working with the affiliate to obtain the required statements and plans to recognize its share in the accounts for the year ending December 31, 2026, when the information is available.

Pharmaceutical business and reach

EIPICO manufactures pharmaceutical products across therapeutic areas including anti-infectives, cardiovascular medicines, analgesics, dermatology products, respiratory medicines and ophthalmics. The company also develops biosimilar and biological products through its EIPICO 3 facility.

Based in Egypt, EIPICO sells into European, African, Asian, Latin American and Commonwealth markets. Its website says the group has more than 400 products, 117 pipeline programs and manufacturing operations serving 78 countries.

EIPICO company facts

  • Company: Egyptian International Pharmaceutical Industries Company
  • ISIN: EGS38081C013
  • Ticker: PHAR.CA
  • Home exchange: Egyptian Exchange
  • Reporting period: January to September 2026
  • Business: Pharmaceutical manufacturing and biosimilar products

Egyptian equities form part of the broader market environment covered in Current market reports.

Find More news and analyses on EIPICO stock.

Disclaimer...
en | EGS38081C013 | PHAR | boerse | 70533191 | bgmi